1 |
GAYEN S. Malignant pleural effusion: presentation, diagnosis, and management[J]. Am J Med, 2022, 135(10): 1188-1192.
|
2 |
WAHLA A S, UZBECK M, SAMEED Y A E L, et al. Managing malignant pleural effusion[J]. Cleve Clin J Med, 2019, 86(2): 95-99.
|
3 |
WALKER S, MERCER R, MASKELL N, et al. Malignant pleural effusion management: keeping the flood gates shut[J]. Lancet Respir Med, 2020, 8(6): 609-618.
|
4 |
LIU Y, WANG L L, SONG Q Q, et al. Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion[J]. Nat Nanotechnol, 2022, 17(2): 206-216.
|
5 |
QURESHI M, THAPA B, MURUGANANDAN S. A narrative review-management of malignant pleural effusion related to malignant pleural mesothelioma[J]. Heart Lung Circ, 2023, 32(5): 587-595.
|
6 |
ROOFCHAYEE N D, ADCOCK I M, MARJANI M, et al. T helper cell subsets in the pleural fluid of tuberculous patients differentiate patients with non-tuberculous pleural effusions[J]. Front Immunol, 2021, 12: 780453.
|
7 |
SONG Z H, LUO W Z, ZHENG H C, et al. Translational nanotherapeutics reprograms immune microenvironment in malignant pleural effusion of lung adenocarcinoma[J]. Adv Healthc Mater, 2021, 10(12): e2100149.
|
8 |
WU X Z, ZHAI K, YI F S, et al. IL-10 promotes malignant pleural effusion in mice by regulating TH 1-and TH 17-cell differentiation and migration[J]. Eur J Immunol, 2019, 49(4): 653-665.
|
9 |
ZHAI K, SHI X Y, YI F S, et al. IL-10 promotes malignant pleural effusion by regulating TH 1 response via an miR-7116-5p/GPR55/ERK pathway in mice[J]. Eur J Immunol, 2020, 50(11): 1798-1809.
|
10 |
SHANG Q H, YU X Y, SUN Q, et al. Polysaccharides regulate Th1/Th2 balance: a new strategy for tumor immunotherapy[J]. Biomedecine Pharmacother, 2024, 170: 115976.
|
11 |
WU X Z, ZHOU Q, LIN H, et al. Immune regulation of toll-like receptor 2 engagement on CD4+T cells in murine models of malignant pleural effusion[J]. Am J Respir Cell Mol Biol, 2017, 56(3): 342-352.
|
12 |
CHEN W L, QIN Y Y, LIU S L. CCL20 signaling in the tumor microenvironment[J]. Adv Exp Med Biol, 2020, 1231: 53-65.
|
13 |
FJAELLEGAARD K, KOEFOD PETERSEN J, REUTER S, et al. Positron emission tomography-computed tomography (PET-CT) in suspected malignant pleural effusion. An updated systematic review and meta-analysis[J]. Lung Cancer, 2021, 162: 106-118.
|
14 |
ZHANG S J, CHEN L C, ZONG Y, et al. Research progress of tumor-derived extracellular vesicles in the treatment of malignant pleural effusion[J]. Cancer Med, 2023, 12(2): 983-994.
|
15 |
MEITEI H T, JADHAV N, LAL G. CCR6-CCL20 axis as a therapeutic target for autoimmune diseases[J]. Autoimmun Rev, 2021, 20(7): 102846.
|
16 |
ADDALA D N, RAHMAN N M, MALDONADO F. Personalized prognostication in malignant pleural effusion: the next step?[J]. Chest, 2021, 160(3): 805-806.
|
17 |
GEORGIEV P, CHARBONNIER L M, CHATILA T A. Regulatory T cells: the many faces of Foxp3[J]. J Clin Immunol, 2019, 39(7): 623-640.
|
18 |
IVANOV I I, MCKENZIE B S, ZHOU L, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+T helper cells[J]. Cell, 2006, 126(6): 1121-1133.
|
19 |
NIU Y R, ZHOU Q. Th17 cells and their related cytokines: vital players in progression of malignant pleural effusion[J]. Cell Mol Life Sci, 2022, 79(4): 194.
|
20 |
NGUYEN Q P, DENG T Z, WITHERDEN D A, et al. Origins of CD4+ circulating and tissue-resident memory T-cells[J]. Immunology, 2019, 157(1): 3-12.
|
21 |
PAIRMAN L, BECKERT L E L, DAGGER M, et al. Evaluation of pleural fluid cytology for the diagnosis of malignant pleural effusion: a retrospective cohort study[J]. Intern Med J, 2022, 52(7): 1154-1159.
|
22 |
HONG H S, MBAH N E, SHAN M R, et al. OXPHOS promotes apoptotic resistance and cellular persistence in TH17 cells in the periphery and tumor microenvironment[J]. Sci Immunol, 2022, 7(77): eabm8182.
|
23 |
CHANGCHIEN C Y, CHEN Y, CHANG H H, et al. Effect of malignant-associated pleural effusion on endothelial viability, motility and angiogenesis in lung cancer[J]. Cancer Sci, 2020, 111(10): 3747-3758.
|
24 |
LEE A Y S, KÖRNER H. The CCR6-CCL20 axis in humoral immunity and T-B cell immunobiology[J]. Immunobiology, 2019, 224(3): 449-454.
|
25 |
KADOMOTO S, IZUMI K, MIZOKAMI A. The CCL20-CCR6 axis in cancer progression[J]. Int J Mol Sci, 2020, 21(15): 5186.
|
26 |
ZHANG H, LI C H, HU F, et al. Auxiliary diagnostic value of tumor biomarkers in pleural fluid for lung cancer-associated malignant pleural effusion[J]. Respir Res, 2020, 21(1): 284.
|
27 |
ZHANG S, ZHANG Y, FENG W, et al. Prediction modeling using routine clinical parameters to stratify survival in malignant pleural mesothelioma patients complicated with malignant pleural effusion[J]. Thorac Cancer, 2021, 12(24): 3304-3309.
|
28 |
XUE G, ZHENG N B, FANG J, et al. Adoptive cell therapy with tumor-specific Th9 cells induces viral mimicry to eliminate antigen-loss-variant tumor cells[J]. Cancer Cell, 2021, 39(12): 1610-1622.e9.
|
29 |
PORCEL J M. Diagnosis and characterization of malignant effusions through pleural fluid cytological examination[J]. Curr Opin Pulm Med, 2019, 25(4): 362-368.
|
30 |
YU Y F, QIAN J, SHEN L, et al. Distinct profile of cell-free DNA in malignant pleural effusion of non-small cell lung cancer and its impact on clinical genetic testing[J]. Int J Med Sci, 2021, 18(6): 1510-1518.
|
31 |
BASHOUR S I, MANKIDY B J, LAZARUS D R. Update on the diagnosis and management of malignant pleural effusions[J]. Respir Med, 2022, 196: 106802.
|
32 |
LUO L S, DENG S, TANG W, et al. Monocytes subtypes from pleural effusion reveal biomarker candidates for the diagnosis of tuberculosis and malignancy[J]. J Clin Lab Anal, 2022, 36(8): e24579.
|
33 |
FAN X, LIU Y Q, LIANG Z G, et al. Diagnostic value of six tumor markers for malignant pleural effusion in 1,230 patients: a single-center retrospective study[J]. Pathol Oncol Res, 2022, 28: 1610280.
|
34 |
ZHANG Y X, LI W H, ZHAI J W, et al. Phenotypic and functional characterizations of CD8+T cell populations in malignant pleural effusion[J]. Exp Cell Res, 2022, 417(1): 113212.
|
35 |
WANG S Y, AN J, HU X R, et al. Single-cell RNA sequencing reveals immune microenvironment of small cell lung cancer-associated malignant pleural effusion[J]. Thorac Cancer, 2024, 15(1): 98-103.
|
36 |
LI X X, BECHARA R, ZHAO J J, et al. IL-17 receptor-based signaling and implications for disease[J]. Nat Immunol, 2019, 20(12): 1594-1602.
|
37 |
GORCZYNSKI R M. IL-17 signaling in the tumor microenvironment[J]. Adv Exp Med Biol, 2020, 1240: 47-58.
|
38 |
BRIUKHOVETSKA D, SUAREZ-GOSALVEZ J, VOIGT C, et al. T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis[J]. Immunity, 2023, 56(1): 143-161.e11.
|
39 |
NI H H, ZHANG H L, LI L, et al. T cell-intrinsic STING signaling promotes regulatory T cell induction and immunosuppression by upregulating FOXP3 transcription in cervical cancer[J]. J Immunother Cancer, 2022, 10(9): e005151.
|
40 |
OIDA T, XU L L, WEINER H L, et al. TGF-beta-mediated suppression by CD4+CD25+T cells is facilitated by CTLA-4 signaling[J]. J Immunol, 2006, 177(4): 2331-2339.
|
41 |
YE Z J, ZHOU Q, GU Y Y, et al. Generation and differentiation of IL-17-producing CD4+T cells in malignant pleural effusion[J]. J Immunol, 2010, 185(10): 6348-6354.
|
42 |
HUYEN PTHI, LI M Y, LI L, et al. Exploring the value of pleural fluid biomarkers for complementary pleural effusion disease examination[J]. Comput Biol Chem, 2021, 94: 107559.
|
43 |
ZHANG S W, GANG X K, YANG S, et al. The alterations in and the role of the Th17/treg balance in metabolic diseases[J]. Front Immunol, 2021, 12: 678355.
|
44 |
LIN H, TONG Z H, XU Q Q, et al. Interplay of Th1 and Th17 cells in murine models of malignant pleural effusion[J]. Am J Respir Crit Care Med, 2014, 189(6): 697-706.
|
45 |
KOYI H, WILANDER E. Refined diagnosis of pleural effusions by immunocytochemistry of cell blocks[J]. Anticancer Res, 2023, 43(2): 669-673.
|
46 |
LEE P H, YANG T Y, CHEN K C, et al. Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors[J]. Sci Rep, 2021, 11(1): 9381.
|
47 |
TANO Z E, KIESGEN S, CHINTALA N K, et al. Ex vivo pleural effusion cultures to study chimeric antigen receptor T cell cytotoxicity in an immunocompetent environment[J]. Cell Rep Methods, 2023, 3(11): 100622.
|
48 |
GHANIM B, ROSENMAYR A, STOCKHAMMER P, et al. Tumour cell PD-L1 expression is prognostic in patients with malignant pleural effusion: the impact of C-reactive protein and immune-checkpoint inhibition[J]. Sci Rep, 2020, 10(1): 5784.
|